Literature DB >> 8991642

Antibody against human immunodeficiency virus type 1 (HIV-1) Tat protein may have influenced the progression of AIDS in HIV-1-infected hemophiliac patients.

M C Re1, G Furlini, M Vignoli, E Ramazzotti, G Zauli, M La Placa.   

Abstract

Retrospective analysis of serum samples from a group of hemophiliac patients who became infected with human immunodeficiency virus type 1 (HIV-1) between 1984 and 1985 has shown that, at variance with other HIV-1-infected patients, at the onset, or at least at a very early phase of HIV-1 infection, they constantly have elevated levels of antibodies against HIV-1-transactivating Tat protein and an absent or barely detectable p24 antigenemia. Anti-Tat antibodies in initial serum samples from hemophiliac patients were probably the consequence of the passive administration of immunoglobulins present in low- or intermediate-purity clotting factor concentrates prepared from HIV-1-infected blood. Furthermore, the analysis of serial serum samples obtained during the course of the disease, in which passively acquired anti-Tat antibodies were substituted by actively produced antibodies, demonstrated an inverse relationship between anti-Tat antibody and p24 anti-genemia levels throughout the observation period. These data seem to suggest that anti-Tat antibody may have some influence on the course of HIV-1 infection.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8991642      PMCID: PMC170285          DOI: 10.1128/cdli.3.2.230-232.1996

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  12 in total

Review 1.  Regulation of HIV-1 gene expression.

Authors:  B R Cullen
Journal:  FASEB J       Date:  1991-07       Impact factor: 5.191

2.  Protein content and factor VIII complex in untreated, treated and monoclonal factor VIII concentrates.

Authors:  M Morfini; D Rafanelli; E Filimberti; S Cinotti; E Piazza; G Longo; P Rossi Ferrini
Journal:  Thromb Res       Date:  1989-10-15       Impact factor: 3.944

3.  Natural antibodies to HIV-tat epitopes and expression of HIV-1 genes in vivo.

Authors:  W J Krone; C Debouck; L G Epstein; P Heutink; R Meloen; J Goudsmit
Journal:  J Med Virol       Date:  1988-11       Impact factor: 2.327

4.  Synergy between basic fibroblast growth factor and HIV-1 Tat protein in induction of Kaposi's sarcoma.

Authors:  B Ensoli; R Gendelman; P Markham; V Fiorelli; S Colombini; M Raffeld; A Cafaro; H K Chang; J N Brady; R C Gallo
Journal:  Nature       Date:  1994-10-20       Impact factor: 49.962

5.  Three novel genes of human T-lymphotropic virus type III: immune reactivity of their products with sera from acquired immune deficiency syndrome patients.

Authors:  S K Arya; R C Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  1986-04       Impact factor: 11.205

6.  Speed of progression to AIDS and degree of antibody response to accessory gene products of HIV-1.

Authors:  P Reiss; J M Lange; A de Ronde; F de Wolf; J Dekker; C Debouck; J Goudsmit
Journal:  J Med Virol       Date:  1990-03       Impact factor: 2.327

7.  An autocrine loop of HIV type-1 Tat protein responsible for the improved survival/proliferation capacity of permanently Tat-transfected cells and required for optimal HIV-1 LTR transactivating activity.

Authors:  G Zauli; M La Placa; M Vignoli; M C Re; D Gibellini; G Furlini; D Milani; M Marchisio; M Mazzoni; S Capitani
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1995-11-01

8.  Is the apparent outbreak of hepatitis A in Belgian hemophiliacs due to a loss of previous passive immunity?

Authors:  K Peerlinck; P Goubau; G Coppens; J Desmyter; J Vermylen
Journal:  Vox Sang       Date:  1994       Impact factor: 2.144

Review 9.  Pathogenesis of human immunodeficiency virus infection.

Authors:  J A Levy
Journal:  Microbiol Rev       Date:  1993-03

10.  Spectrum of natural antibodies against five HTLV-III antigens in infected individuals: correlation of antibody prevalence with clinical status.

Authors:  G Franchini; M Robert-Guroff; A Aldovini; N C Kan; F Wong-Staal
Journal:  Blood       Date:  1987-02       Impact factor: 22.113

View more
  10 in total

1.  Pronounced acute immunosuppression in vivo mediated by HIV Tat challenge.

Authors:  S S Cohen; C Li; L Ding; Y Cao; A B Pardee; E M Shevach; D I Cohen
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-14       Impact factor: 11.205

2.  The human immunodeficiency virus type 1 tat protein enhances Cryptosporidium parvum-induced apoptosis in cholangiocytes via a Fas ligand-dependent mechanism.

Authors:  Steven P O'Hara; Aaron J Small; Jeremy B Nelson; Andrew D Badley; Xian-Ming Chen; Gregory J Gores; Nicholas F Larusso
Journal:  Infect Immun       Date:  2006-11-21       Impact factor: 3.441

3.  IgG subclass profiles in infected HIV type 1 controllers and chronic progressors and in uninfected recipients of Env vaccines.

Authors:  Kaustuv Banerjee; P J Klasse; Rogier W Sanders; Florencia Pereyra; Elizabeth Michael; Min Lu; Bruce D Walker; John P Moore
Journal:  AIDS Res Hum Retroviruses       Date:  2010-04       Impact factor: 2.205

4.  HIV-1 Tat-induced platelet activation and release of CD154 contribute to HIV-1-associated autoimmune thrombocytopenia.

Authors:  J Wang; W Zhang; M A Nardi; Z Li
Journal:  J Thromb Haemost       Date:  2011-03       Impact factor: 5.824

5.  A Tat subunit vaccine confers protective immunity against the immune-modulating activity of the human immunodeficiency virus type-1 Tat protein in mice.

Authors:  S M Agwale; M T Shata; M S Reitz; V S Kalyanaraman; R C Gallo; M Popovic; D M Hone
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-02       Impact factor: 11.205

6.  Transactivation and signaling functions of Tat are not correlated: biological and immunological characterization of HIV-1 subtype-C Tat protein.

Authors:  Nagadenahalli Byrareddy Siddappa; Mohanram Venkatramanan; Prasanna Venkatesh; Mohanbabu Vijayamma Janki; Narayana Jayasuryan; Anita Desai; Vasanthapuram Ravi; Udaykumar Ranga
Journal:  Retrovirology       Date:  2006-08-18       Impact factor: 4.602

7.  The grafting of universal T-helper epitopes enhances immunogenicity of HIV-1 Tat concurrently improving its safety profile.

Authors:  Venkatesh P Kashi; Rajesh A Jacob; Raghavendra A Shamanna; Malini Menon; Anangi Balasiddaiah; Rebu K Varghese; Mahesh Bachu; Udaykumar Ranga
Journal:  PLoS One       Date:  2014-12-22       Impact factor: 3.240

8.  Breadth and magnitude of antigen-specific antibody responses in the control of plasma viremia in simian immunodeficiency virus infected macaques.

Authors:  Bapi Pahar; Carys S Kenway-Lynch; Preston Marx; Sudesh K Srivastav; Celia LaBranche; David C Montefiori; Arpita Das
Journal:  Virol J       Date:  2016-12-01       Impact factor: 4.099

9.  Association between different anti-Tat antibody isotypes and HIV disease progression: data from an African cohort.

Authors:  Francesco Nicoli; Mkunde Chachage; Petra Clowes; Asli Bauer; Dickens Kowour; Barbara Ensoli; Aurelio Cafaro; Leonard Maboko; Michael Hoelscher; Riccardo Gavioli; Elmar Saathoff; Christof Geldmacher
Journal:  BMC Infect Dis       Date:  2016-07-22       Impact factor: 3.090

Review 10.  The Glutamate System as a Crucial Regulator of CNS Toxicity and Survival of HIV Reservoirs.

Authors:  Anna Maria Gorska; Eliseo A Eugenin
Journal:  Front Cell Infect Microbiol       Date:  2020-06-24       Impact factor: 5.293

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.